1.Management of portal hypertensive gastropathy and other bleeding.
Clinical and Molecular Hepatology 2014;20(1):1-5
A major cause of cirrhosis related morbidity and mortality is the development of variceal bleeding, a direct consequence of portal hypertension. Less common causes of gastrointestinal bleeding are peptic ulcers, malignancy, angiodysplasia, etc. Upper gastrointestinal bleeding has been classified according to the presence of a variceal or non-variceal bleeding. Although non-variceal gastrointestinal bleeding is not common in cirrhotic patients, gastroduodenal ulcers may develop as often as non-cirrhotic patients. Ulcers in cirrhotic patients may be more severe and less frequently associated with chronic intake of non-steroidal anti-inflammatory drugs, and may require more frequently endoscopic treatment. Portal hypertensive gastropathy (PHG) refers to changes in the mucosa of the stomach in patients with portal hypertension. Patients with portal hypertension may experience bleeding from the stomach, and pharmacologic or radiologic interventional procedure may be useful in preventing re-bleeding from PHG. Gastric antral vascular ectasia (GAVE) seems to be different disease entity from PHG, and endoscopic ablation can be the first-line treatment.
Gastric Antral Vascular Ectasia/complications
;
Gastric Mucosa/pathology
;
Gastrointestinal Hemorrhage/*etiology
;
Humans
;
Hypertension, Portal/*complications/prevention & control
;
Liver Cirrhosis/complications
;
Peptic Ulcer/complications
2.Portal Hypertensive Gastropathy and Gastric Antral Vascular Ectasia.
The Korean Journal of Gastroenterology 2010;56(3):186-191
Portal hypertensive gastropathy (PHG) is a term used to define the endoscopic findings of gastric mucosa with a characteristic mosaic-like pattern with or without red spots, and a common finding in patients with portal hypertension. These endoscopic findings correspond to dilated mucosal capillaries without inflammation. The pathogenesis of PHG in not well known, but portal hypertension and some humoral factors seem to be crucial factors for its development. Pharmacological (e.g. propranolol), or interventional radiological (such as transjugular intrahepatic portosystemic shunt) procedures may be useful in preventing re-bleeding from PHG. The classic features of gastric antral vascular ectasia (GAVE) syndrome include red, often haemorrhagic lesions predominantly located in the gastric antrum which can result in significant blood loss. Although the pathogenesis of GAVE is not clearly defined, it seems to be a separate disease entity from PHG, because GAVE generally does not respond to a reduction of portal pressures. Endoscopic ablation (such as argon plasma coagulation) is the first-line treatment of choice. This review will focus on the incidence, clinical importance, etiology, pathophysiology, and treatment of PHG and GAVE syndrome in the setting of portal hypertension.
Esophageal and Gastric Varices/*diagnosis/etiology/therapy
;
Gastric Antral Vascular Ectasia/*diagnosis/etiology/therapy
;
Gastric Mucosa/metabolism/pathology
;
Humans
;
Hypertension, Portal/*complications
;
Portasystemic Shunt, Transjugular Intrahepatic
;
Vasodilator Agents/therapeutic use
3.Portal hypertensive gastropathy.
Chinese Journal of Hepatology 2009;17(4):254-256
Animals
;
Diagnosis, Differential
;
Disease Models, Animal
;
Gastric Antral Vascular Ectasia
;
diagnosis
;
pathology
;
Gastric Mucosa
;
pathology
;
Gastrointestinal Hemorrhage
;
etiology
;
pathology
;
therapy
;
Gastroscopy
;
Humans
;
Hypertension, Portal
;
complications
;
epidemiology
;
pathology
;
Intestinal Mucosa
;
pathology
;
Liver Cirrhosis
;
complications
;
pathology
;
Liver Cirrhosis, Experimental
;
complications
;
pathology
;
Rats
;
Stomach Diseases
;
epidemiology
;
etiology
;
pathology
;
therapy